Hereditary Multiple Osteochondromas
OVERVIEW
Hereditary multiple osteochondromas (HMO) is a rare genetic disorder characterized by multiple benign (noncancerous) bone tumors that are covered by cartilage (osteochondromas), often on the growing end (metaphysis) of the long bones of the legs, arms, and digits. These osteochondromas usually continue to grow until shortly after puberty and may lead to bone deformities, skeletal abnormalities, short stature, nerve compression and reduced range of motion. Hereditary multiple osteochondromas is inherited as an autosomal dominant genetic condition and is associated with abnormalities (mutations) in the EXT1or EXT2 gene.Hereditary multiple osteochondromas was formerly called hereditary multiple exostoses.
SYMPTOMS
Hereditary multiple osteochondromas is a rare disorder that affects bone growth. Bony tumors (exostoses or osteochondromas), covered with cartilage, typically appear in the growth zones (metaphyses) of the long bones adjacent to the areas where tendon and muscles attach to the bone. These growths vary in size and number among affected individuals, even within the same family. Some individuals will present with a few large “lumps” while others will show several small growths. The median age of diagnosis is three years and almost all affected individuals are diagnosed by 12 years of age.
In many cases, no treatment is required. If the exostoses are small, they may have little or no effect on the patient. However, in more severe cases, the growths may cause deformities of the forearm, knees, ankles, spine and/or pelvis. They may impose upon nerves, tendons and/or blood vessels, and interfere with movement or circulation, causing substantial pain as a result of pinched nerves or compressed tendons.
Bones that develop exostoses most often are the upper arm (humerus), forearm, knee and shoulder blades (scapulae). Bowing of the forearm and ankle are the problems that most often require surgical correction.
Approximately 40 percent of affected individuals have mild short stature as a result of shortened and/or bowed legs. If the vertebrae are affected, spinal cord compression may result, causing numbness and/ or paralysis. Urinary obstruction has been observed due to exostoses of the pelvic area.
The bony growths that characterize this disorder continue to grow until shortly after puberty at which time normally new growth no longer develops. The risk for development of malignant (cancerous) tumors, mostly chondrosarcomas, is approximately 1 to 5%.
Causes
HMO is a genetic disorder. In 90% of people with HMO, the condition happens when there is a change (mutation) in the EXT1 or EXT2 gene (a piece of DNA that tells your body how to make certain proteins). For the other 10%, the genetic cause is unknown.
Most often, the condition happens when parents pass these genetic mutations to their children. But some people with HMO don’t have a parent with this genetic mutation. Sometimes, this condition can happen even if no one else in the family has HMO.
AFFECTED POPULATIONS
The prevalence of HMO has been estimated to be about 1 of 50,000 live births. A high prevalence of this disorder has been reported in some isolated communities. Hereditary multiple osteochondromas is a disorder that affects males and females in equal numbers but in general males tend to be more severely affected.
DISORDERS WITH SIMILAR SYMPTOMS
Symptoms of the following disorders can be similar to those of hereditary multiple exostoses. Comparisons may be useful for a differential diagnosis.
Metachondromatosis is a very rare autosomal dominant genetic disorder characterized by both enchondromatosis and multiple exostoses. Enchondromatosis is characterized by slow growing tumors of cartilage cells near the ends of the long bones. The multiple exostoses associated with this condition occur mostly in the digits and do not lead to deformity of the long bones or joints. This condition is caused by a mutation in the PTPN11 gene.
Langer-Giedion syndrome, also known as trichorhinophalangeal syndrome type II (TRPS2), is an extremely rare inherited multisystem disorder. TRPS2 is characterized by fine, thin hair; unusual facial features; progressive growth retardation resulting in short stature (dwarfism); abnormally short fingers and toes (brachydactyly); “cone-shaped” formation of the “growing ends” of certain bones (epiphyseal coning); and/or development of multiple bony growths (exostoses) projecting outward from the surfaces of various bones of the body. In addition, affected individuals may exhibit unusually flexible (hyperextensible) joints, diminished muscle tone (hypotonia), excess folds of skin (redundant skin), and/or discolored elevated spots on the skin (maculopapular nevi). Affected individuals may also exhibit mild to severe mental retardation, hearing loss (sensorineural deafness), and/or delayed speech development. The range and severity of symptoms varies greatly from case to case. TRPS2 is due to the absence of genetic material (chromosomal deletions) on chromosome 8. The size of the deletion varies from case to case but includes the EXT1 gene. (For more information on this disorder, choose “trichorhinophalangeal syndrome type II ” as your search term in the Rare Disease Database.)
11p11 deletion syndrome is a condition caused by a deletion of adjacent genes on chromosome 11 (contiguous gene syndrome) including the EXT2 gene. This condition is characterized by ossification defects of the skull, multiple exostoses and sometimes craniofacial abnormalities and mental retardation.
STANDARD THERAPIES
The diagnosis of HMO is based on clinical features, X-ray findings and family history. Molecular genetic testing of the EXT1 and EXT2 genes is available to confirm the diagnosis.
Treatment
Surgery may be required to relieve pain, improve movement, restore normal circulation, or for cosmetic reasons. Malignant degeneration of a tumor is treated surgically, possibly in combination with chemotherapy and radiation therapy.
Most of the malignant degenerations to cancers are to cartilage tumors or chondrosarcomas, which are slow growing and generally insensitive to chemotherapy.
Monitoring the size of affected bones by annual scans to screen for malignant degeneration is sometimes recommended. Rapid growth and increased pain are signs of a possible malignant change.
Genetic counseling is recommended for affected individuals and their families. Other treatment is symptomatic and supportive.
Type of Doctor Department : A Genetics physician
Comments
Post a Comment